MetaVia to Present at Upcoming Investor and Industry Conferences
MetaVia (Nasdaq: MTVA), a clinical-stage biotech company specializing in cardiometabolic diseases, has announced its participation in several upcoming investor and industry conferences from September to October 2025.
CEO Hyung Heon Kim will attend the Wells Fargo Healthcare Conference (Sept 3-5), participate in a fireside chat at the H.C. Wainwright Global Investment Conference (Sept 8-10), present at the Obesity Science & Innovation Congress (Sept 16-17), and attend the Fierce Biotech Week (Oct 7-9). At the Obesity Science conference, Kim will showcase DA-1726, the company's dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity treatment.
MetaVia (Nasdaq: MTVA), azienda biotech in fase clinica specializzata nelle malattie cardiometaboliche, ha comunicato la sua partecipazione a diversi incontri con investitori e conferenze di settore previsti tra settembre e ottobre 2025.
Il CEO Hyung Heon Kim sarà presente al Wells Fargo Healthcare Conference (3-5 settembre), interverrà in un fireside chat al H.C. Wainwright Global Investment Conference (8-10 settembre), terrà una presentazione all'Obesity Science & Innovation Congress (16-17 settembre) e parteciperà al Fierce Biotech Week (7-9 ottobre). Durante l'evento Obesity Science, Kim presenterà DA-1726, l'analogo duale dell'oxyntomodulina dell'azienda che agisce su GLP1R e GCGR per il trattamento dell'obesità.
MetaVia (Nasdaq: MTVA), empresa biotecnológica en fase clínica especializada en enfermedades cardiometabólicas, ha anunciado su asistencia a varias conferencias para inversores y del sector programadas entre septiembre y octubre de 2025.
El CEO Hyung Heon Kim asistirá al Wells Fargo Healthcare Conference (3-5 de septiembre), participará en un fireside chat en el H.C. Wainwright Global Investment Conference (8-10 de septiembre), presentará en el Obesity Science & Innovation Congress (16-17 de septiembre) y acudirá al Fierce Biotech Week (7-9 de octubre). En la conferencia sobre obesidad, Kim dará a conocer DA-1726, el agonista análogo dual de oxyntomodulina de la compañía dirigido a GLP1R y GCGR para el tratamiento de la obesidad.
MetaVia (Nasdaq: MTVA)는 심장대사 질환 분야의 임상 단계 바이오테크 기업으로, 2025년 9월부터 10월 사이 개최되는 여러 투자자 및 업계 콘퍼런스에 참가할 것이라고 발표했습니다.
CEO 김형헌(Hyung Heon Kim)은 Wells Fargo Healthcare Conference(9월 3–5일)에 참석하고, H.C. Wainwright Global Investment Conference(9월 8–10일)에서 파이어사이드 채팅에 참여하며, Obesity Science & Innovation Congress(9월 16–17일)에서 발표를 하고, Fierce Biotech Week(10월 7–9일)에 참석할 예정입니다. Obesity Science 콘퍼런스에서 김 CEO는 회사의 이중 oxyntomodulin 유사체 작용제인 DA-1726을 소개할 예정이며, 이는 GLP1R 및 GCGR을 표적해 비만 치료를 목적으로 합니다.
MetaVia (Nasdaq: MTVA), une société biotechnologique en phase clinique spécialisée dans les maladies cardiométaboliques, a annoncé sa participation à plusieurs conférences pour investisseurs et évènements sectoriels prévus entre septembre et octobre 2025.
Le CEO Hyung Heon Kim assistera au Wells Fargo Healthcare Conference (3-5 septembre), prendra part à un fireside chat lors du H.C. Wainwright Global Investment Conference (8-10 septembre), présentera au Obesity Science & Innovation Congress (16-17 septembre) et participera au Fierce Biotech Week (7-9 octobre). Lors du congrès sur l'obésité, Kim présentera DA-1726, l'agoniste analogue dual d'oxyntomoduline de la société ciblant GLP1R et GCGR pour le traitement de l'obésité.
MetaVia (Nasdaq: MTVA), ein klinisch geführtes Biotech-Unternehmen mit Schwerpunkt auf kardiometabolischen Erkrankungen, hat seine Teilnahme an mehreren Investoren- und Branchenkonferenzen von September bis Oktober 2025 angekündigt.
CEO Hyung Heon Kim wird an der Wells Fargo Healthcare Conference (3.–5. Sept.), in einem Fireside-Chat auf der H.C. Wainwright Global Investment Conference (8.–10. Sept.) teilnehmen, beim Obesity Science & Innovation Congress (16.–17. Sept.) präsentieren und die Fierce Biotech Week (7.–9. Okt.) besuchen. Auf der Obesity Science-Konferenz wird Kim DA-1726 vorstellen, den dualen Oxyntomodulin-Analogon-Agonisten des Unternehmens, der auf GLP1R und GCGR zur Behandlung von Adipositas abzielt.
- None.
- None.
- September 3-5: Wells Fargo Healthcare Conference. Hyung Heon Kim, President and Chief Executive Officer will attend this conference in
Boston, Massachusetts . - September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view beginning Friday, September 5, 2025, at 7:00 am ET on the H.C. Wainwright Conference Portal and on the Event Calendar page of the MetaVia website https://ir.metaviatx.com/events-presentations/event-calendar.
Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. - September 16-17: Obesity Science & Innovation 2025 Congress. Mr. Kim will present a company overview with a focus on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity, at this conference in
Boston, Massachusetts . - October 7-9: Fierce Biotech Week. Mr. Kim will attend this conference in
Boston, Massachusetts .
To schedule a meeting with management outside of these events, investors can contact Michael Miller at mmiller@rxir.com.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-present-at-upcoming-investor-and-industry-conferences-302536713.html
SOURCE MetaVia Inc.
FAQ
When is MetaVia (MTVA) presenting at the H.C. Wainwright Conference 2025?
What is MetaVia's (MTVA) drug candidate DA-1726?
Which conferences will MetaVia (MTVA) attend in September 2025?
How can investors schedule meetings with MetaVia (MTVA) management?
